• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (33)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in this journal  Topic Collections  • Quality of Care  • Evidence-Based Medicine  • Statistics and Research Methods  • Surgery  • Surgical Interventions  • Surgical Interventions, Other  • Review  • Prognosis/ Outcomes  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Systematic Review and Meta-analysis of Randomized Clinical Trials

Marco Ranucci, MD; Giuseppe Isgrò, MD; Giorgio Soro, MD; Daniela Conti, MD; Barbara De Toffol, MD

Arch Surg. 2008;143(3):296-304.

Objective  To investigate the efficacy and safety of recombinant activated factor VII (rFVIIa) treatment in patients undergoing major surgical procedures.

Data Sources  Relevant studies were searched in BioMedCentral, CENTRAL, PubMed, and PubMed Central.

Study Selection  Only randomized controlled trials on humans undergoing major surgery were included. Efficacy was determined as the rate of patients receiving allogeneic packed red blood cells; safety was assessed in terms of thromboembolic complications and mortality rate.

Data Extraction  We followed the Cochrane Collaboration method for data extraction and internal validity procedures, as well as the Quality of Reporting of Meta-analyses statement.

Data Synthesis  Seven randomized controlled trials met the inclusion criteria. Treatment with rFVIIa is associated with a reduced risk of receiving allogeneic packed red blood cells (odds ratio, 0.29; 95% confidence interval, 0.10-0.80). In a subgroup analysis, only patients receiving at least 50 µg/kg of rFVIIa had a significant benefit (odds ratio, 0.43; 95% confidence interval, 0.23-0.78). No differences in thromboembolic complications and mortality rates were observed.

Conclusions  Treatment with rFVIIa is effective in reducing the rate of patients undergoing transfusion with allogeneic packed red blood cells. However, the cost-benefit ratio is favorable only in patients who need a huge number of packed red blood cell units. No safety concerns arise from the present study.

Author Affiliations: Department of Cardiovascular Anaesthesia, IRCCS Policlinico S. Donato, Milan, Italy.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Administration of Recombinant Activated Factor VII in Major Thoracic Operations
Ali-Asghar Alavi, Sayed Mahdi Jalali, Mohammad R. Rasouli, and Payam Eghtesadi-Araghi
Arch Surg. 2008;143(10):1021.
EXTRACT | FULL TEXT  

Administration of Recombinant Activated Factor VII in Major Thoracic Operations—Reply
Marco Ranucci
Arch Surg. 2008;143(10):1021.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials—Invited Critique
M. Margaret Knudson
Arch Surg. 2008;143(3):304.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
Ferraris et al.
Ann. Thorac. Surg. 2011;91:944-982.
ABSTRACT | FULL TEXT  

Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis
Lin et al.
CMAJ 2011;183:E9-E19.
ABSTRACT | FULL TEXT  

Chapter 76 Perioperative management of the high-risk cardiac surgery patient
Ranucci et al.
The ESC Textbook of Acute and Intensive Cardiac Care 2010;1:med-9780199584314-chapter-med-9780199584314-chapter.
ABSTRACT | FULL TEXT  

Unlabeled uses of factor VIIa (recombinant) in pediatric patients
Hong and Stachnik
Am J Health Syst Pharm 2010;67:1909-1919.
ABSTRACT | FULL TEXT  

Management of Spontaneous Nontraumatic Intracranial Hemorrhage
Parker et al.
Journal of Pharmacy Practice 2010;23:398-407.
ABSTRACT  

Thromboembolic Events With Recombinant Activated Factor VII in Spontaneous Intracerebral Hemorrhage: Results From the Factor Seven for Acute Hemorrhagic Stroke (FAST) Trial
Diringer et al.
Stroke 2010;41:48-53.
ABSTRACT | FULL TEXT  

Effect of Recombinant Activated Factor VII in Critical Bleeding: Clinical Experience of a Single Center
Sartori et al.
CLIN APPL THROMB HEMOST 2009;15:628-635.
ABSTRACT  

Administration of Recombinant Activated Factor VII in Major Thoracic Operations
Alavi et al.
Arch Surg 2008;143:1021-1021.
FULL TEXT  

Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials
Hardy et al.
Ann. Thorac. Surg. 2008;86:1038-1048.
ABSTRACT | FULL TEXT